Key result
Neither NT-proBNP (p=0.1857) nor sST2 (p=0.7851) concentrations were able to differentiate patients with severe versus non-severe degenerative aortic stenosis and preserved left ventricular ejection fraction.
Why the study?
Do sST2 and NT-proBNP levels differentiate the severity of aortic stenosis in patients with preserved LVEF?
Cross-Sectional (n=69)
No
Do sST2 and NT-proBNP levels differentiate the severity of aortic stenosis in patients with preserved LVEF?
p-value: p=0.1857 (NT-proBNP); 0.7851 (sST2)
In patients with symptomatic degenerative aortic stenosis and preserved LVEF, neither NT-proBNP nor sST2 concentrations can reliably differentiate between severe and non-severe AS.
Findings do not support NT-proBNP or sST2 for aortic stenosis severity grading in preserved LVEF; leaves open identification of reliable noninvasive markers.
Introduction: Aortic stenosis (AS) is the most common acquired valvular heart disease. The early identification of patients with severe AS is crucial. NT-proBNP is a well-known biomarker of pressure overload, and its role in patients with AS has been demonstrated in previous studies. Another, less well-known biomarker of pressure overload is sST2 protein, and its role in AS is unclear. Aim: To evaluate the utility of sST2 protein, NT-proBNP and selected clinical parameters in the assessment of degenerative AS severity in a population with preserved left ventricular ejection fraction (LVEF). Material and methods: Sixty-nine consecutive patients (mean age: 68.42 12.58 years, 55.07% male) with symptomatic degenerative AS and preserved LVEF 45% were prospectively included. At enrollment complete transthoracic echocardiographic examination, ECG analysis, and standard laboratory tests including NT-proBNP were performed and blood samples for sST2 were obtained. Results: There were 43 (62.32%) patients with severe AS. The multivariate stepwise linear regression models revealed that only systolic blood pressure (SBP), Sokolow-Lyon index and left ventricular end-diastolic diameter (LVEDD) were independently associated with severe AS. Spearman correlation coefficients analysis showed no correlations between sST2 levels and a mild to moderate correlation between NT-proBNP concentration and parameters of AS severity. However, levels of NT-proBNP (p = 0.1857) and sST2 (p = 0.7851) did not differentiate patients according to severity of AS. Conclusions: In the study population with degenerative AS and preserved LVEF neither the NT-proBNP nor sST2 concentrations can be used to differentiate patients according to the severity of AS.
No takes yet. Share an insight, caveat, or question.
Sobczak et al. (2017) conducted a cross-sectional in Degenerative aortic stenosis with preserved left ventricular ejection fraction (n=69). NT-proBNP and sST2 biomarkers vs. Non-severe aortic stenosis was evaluated on Differentiation of severe versus non-severe aortic stenosis (p=0.1857 (NT-proBNP); 0.7851 (sST2)). Neither NT-proBNP (p=0.1857) nor sST2 (p=0.7851) concentrations were able to differentiate patients with severe versus non-severe degenerative aortic stenosis and preserved left ventricular ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: